Introduction
============

Compared with standard first-line platinum-based chemotherapy, first- and second-generation tyrosine kinase inhibitors (TKIs) blocking epidermal growth factor receptor (EGFR) signaling have improved outcomes for lung cancer patients with activating mutations in the *EGFR* gene \[[@mdx396-B1]\]. However, acquired resistance through a second-site mutation at position 790 (*T790M*) in the EGFR kinase domain limits the potential of these therapies \[[@mdx396-B4]\]. Third-generation T790M inhibitors such as osimertinib \[[@mdx396-B5]\], rociletinib \[[@mdx396-B6]\], olmutinib \[[@mdx396-B7]\], and nazartinib \[[@mdx396-B8]\] are covalent mutant-selective EGFR-TKIs targeting sensitizing mutations in the presence of the *T790M*. Although these drugs are showing clinical benefit for lung cancer patients \[[@mdx396-B9], [@mdx396-B10]\], resistance occurs and the lack of further treatment options currently represents a major challenge in the field.

Recent data suggest several tertiary mutations in *EGFR*, such as *C797S*, *L798I* and *L718Q* as mechanisms of resistance to third-generation TKIs targeting *EGFR T790M* \[[@mdx396-B11]\]. Finally, osimertinib resistance is being linked to either *ERBB2* copy number gain, *MET* gene amplification, *NRAS E63K* or *KRAS G12S* mutations \[[@mdx396-B14]\].

Methods
=======

Here, present the case of a patient with a metastatic lung adenocarcinoma. For the described study, we obtained tumor sample from lung tumor and brain metastasis. This metastasis was also used for the patient-derived orthotopic xenograft (PDOX) development by injecting cells in mouse brain. All samples from both patient and PDOX, preserved as formalin-fixed paraffin-embedded (FFPE), were initially genotyped by Amplicon-seq and the orthotopically grown metastases from the PDOX were used for the single-cell analysis. Droplet digital PCR (ddPCR) study was carried out using all the available samples from patient and PDOX. In addition, for the ddPCR study, samples from 20 patients diagnosed with non-small-cell lung cancer (NSCLC) at different stages of their treatment were selected. Full description in [supplementary Methods](#sup1){ref-type="supplementary-material"}, available at *Annals of Oncology* online.

Results
=======

To identify new mechanisms of resistance to third-generation EGFR-TKIs and define novel treatment strategies, we analyzed the molecular evolution of tumor samples from an *EGFR*-mutant lung cancer patient treated with consecutive lines of EGFR-TKIs (Figure [1](#mdx396-F1){ref-type="fig"}A--C). All available samples were analyzed using targeted re-sequencing detecting mutations in a panel of 57 oncogenes and tumor suppressors \[[@mdx396-B11]\] ([supplementary Table S1](#sup4){ref-type="supplementary-material"}, available at *Annals of Oncology* online) or copy number alterations using an nCounter panel. At diagnosis, the patient presented an advanced lung adenocarcinoma with mediastinal lymph nodes, lung and brain metastases initially treated with whole brain radiotherapy (Figure [1](#mdx396-F1){ref-type="fig"}C). Since the primary lung adenocarcinoma sample harbored exon 19 deletion in *EGFR*, the patient was treated with erlotinib (Figure [1](#mdx396-F1){ref-type="fig"}D). All lesions initially responded to EGFR blockade until bone metastasis appeared after 9 months of erlotinib treatment (Figure [1](#mdx396-F1){ref-type="fig"}C and E). At that time, the patient was included in a phase I clinical trial (AURA trial), receiving treatment with osimertinib. The analysis of cfDNA detected an additional *EGFR T790M* mutation (Figure [1](#mdx396-F1){ref-type="fig"}C and D). Therapy initially reduced brain metastasis and treatment with osimertinib was sustained 21 months until the progressive metastatic brain lesion enlarged and required surgical resection (Figure [1](#mdx396-F1){ref-type="fig"}C and E). Following brain surgery, osimertinib was continued for and additional 3 months due to clinical benefit. NGS analyses on this surgical specimen once again showed the deletion of exon 19 in *EGFR* and the *TP53 Q317fs* mutation and loss of *EGFR T790M* mutation (Figure [1](#mdx396-F1){ref-type="fig"}D). Additionally, we identified a high-level amplification of the *MET* oncogene that was confirmed by fluorescent *in situ* hybridization \[[@mdx396-B17]\] (FISH) *(*copy number of \>40; *MET*/CEN7 ratio of \>5) (Figure [1](#mdx396-F1){ref-type="fig"}D and F), and high levels of c-MET protein by immunohistochemistry (Figure [1](#mdx396-F1){ref-type="fig"}G). HER2 amplification was excluded as a resistance mechanism since no amplification was detected by FISH (*ERBB2* gene copy number of 6; *ERBB2*/CEN17 \[[@mdx396-B18]\] ratio of 1.1), or by immunohistochemistry (Figure [1](#mdx396-F1){ref-type="fig"}F and data not shown). The emergence of this *MET* amplification in the context of an exon 19 deletion of *EGFR* and a regression of *EGFR T790M* mutation led us to combine EGFR and c-MET inhibitors to block the growth of the progressive brain metastasis \[[@mdx396-B19]\]. Unfortunately, the patient suffered a rapid relapse and died soon after brain surgery.

![Evolution and plasticity of acquired resistance mechanisms to osimertinib in NSCLC harboring *EGFR* mutation. (A) Study of the molecular profiling of metastatic brain biopsy specimen of female patient with NSCLC exon 19 deletion and *T790M* mutation treated with osimertinib. (A, C and D) ADC, adenocarcinoma. (B) Morphological appearance of primary and metastatic lung lesions (haematoxylin and eosin, 20×). (C) Serial of target tumor lesions measures and the lower panel displays anti-EGFR treatment, imaging evaluation and genotyping along the evolution of the metastatic disease. (D) Molecular profiling of paired biopsies: baseline and at the time of progression to erlotinib and osimertinib. n. d., non-determined. (E) Representative brain MRI and CT scans at the time points indicated are provided; the largest brain target lesion is indicated with an arrow. (F) FISH analyses showing the presence of *MET* amplification in the brain metastasis after relapse osimertinib (*MET* gene, green signals; CEN7, red signals; 100×). (G) High expression of *cMET* and *EGFR* proteins was observed in brain lesion by immunohistochemistry. No expression for *HER2* was found (2.5×).](mdx396f1){#mdx396-F1}

At the time of surgery of brain metastasis, we obtained surgical tumor tissue to implant orthotopically in immunodeficient nude mice, generating an orthoxenograft or PDOX model (Figure [2](#mdx396-F2){ref-type="fig"}A) \[[@mdx396-B20], [@mdx396-B21]\]. PDOXs present high concordance with the original clinical tumors \[[@mdx396-B22], [@mdx396-B23]\]. In this particular case, PDOX not only faithfully recapitulated the patient's histology but also preserved *MET* amplification (Figure [2](#mdx396-F2){ref-type="fig"}B and C) and similar *EGFR* status (total proteins by IHC and CNV using FISH) ([supplementary Figure S3](#sup3){ref-type="supplementary-material"} and Table S4, available at *Annals of Oncology* online). This model allowed us to explore the efficacy of an EGFR inhibitor and c-MET inhibitor combined.

![Orthotopic patient-derived xenograft (PDOX) models using the same fresh metastatic brain biopsy of our patient at the time of progression to osimertinib. (A) Different PDOX cohorts that received treatment with vehicle, osimertinib, cisplatin/pemetrexed, afatinib, capmatinib and a combination of capmatinib and afatinib (capmatinib/afatinib). (A, B and E) Cis, cisplatin; Pem, pemetrexed; Cap, capmatinib; Afa, afatinib. (B) Representative images showing high similarity between patient brain metastasis and its PDX (20×). (C) *MET* gene amplification by FISH in the PDX (*MET* gene, green signals; CEN7, red signals; 100×). (D) Kaplan--Meier survival analysis for the different PDOX treated cohorts. (E) Genotyping of PDOX samples obtained from mice that progressed to the different treatments. VAF, variant allele frequency. (F) Representation of clonal evolution of the acquired resistance. *KRAS G12C* and *EGFR T790M* mutations were only detected by ddPCR in patient lesions. n. d., non-determined; ADC, adenocarcinoma.](mdx396f2){#mdx396-F2}

Passable biopsies were orthotopically implanted into the brain of 35 nude mice that were randomized and treated with vehicle, cisplatin/pemetrexed (standard chemotherapy), osimertinib (EGFR sensitizing and *T790M* resistance mutation inhibitor), afatinib (ErbB-1/2/4 inhibitor), capmatinib (c-MET inhibitor) and a combination of capmatinib and afatinib (Figure [2](#mdx396-F2){ref-type="fig"}A). All treatments were administered during 21 days. Capmatinib alone or combined with afatinib showed superior efficacy, significantly increasing the overall survival of mice (Figure [2](#mdx396-F2){ref-type="fig"}D). Strikingly, none of the capmatinib/afatinib treated mice displayed weight loss, increased intracranial pressure, presented any tumor evidence, or scaring in the brain or any other analyzed tissues after 300 days upon tumor implantation. These data demonstrate that capmatinib/afatinib treatment cured all mice. In the case of capmatinib monotherapy, two mice died 2 months after tumor implantation presenting brain tumors upon necropsy. Another two mice died after 9 months with no brain tumor, but one presented a lung metastasis and the other a mesenteric lesion. When treated with afatinib alone, all mice progressed with growing brain tumors and had to be killed earlier after treatment initiation. Similarly, PDOX treated with osimertinib did not show any benefit, confirming the resistance observed in the patient. In summary, c-MET, as opposed to EGFR blockade, was effective. The combination of the two, however, was the most potent therapy showing curative potential.

We then genotyped PDOX samples obtained from mice that progressed to the different treatments (Figure [2](#mdx396-F2){ref-type="fig"}G). All xenograft tissues showed the same exon 19 deletion in *EGFR*, *TP53 Q317fs* mutation as well as *MET* amplification detected in the original patient's brain metastasis (Figure [2](#mdx396-F2){ref-type="fig"}C, E and F). In addition, we observed a subclonal *TP53 Q165K* mutation in some xenografts. Interestingly, we detected the emergence of a subclonal *KRAS G12C* mutation exclusively in xenograft tumors from mice treated with afatinib or capmatinib as monotherapy. This data suggested the surfacing of minor preexisting *KRAS G12C* mutant clones as a mechanism of resistance to effective EGFR or c-MET signaling blockade. In the original patient's metastatic brain tumor biopsy, we actually confirmed the existence of EGFR *T790M* and KRAS *G12C* mutations at low-allele frequencies using ddPCR \[[@mdx396-B24]\].

To study this phenomenon further, we evaluated clonal distribution within xenograft tumor samples by single-cell transcriptome analysis (massive parallel single-cell RNA-sequencing, MARS-Seq) \[[@mdx396-B25], [@mdx396-B26]\]. We sequenced 197 randomly selected cells from a tumor xenograft that grew in the brain of a capmatinib treated mouse and presented a *KRAS G12C* mutation and an exon 19 deletion in *EGFR* (Figure [2](#mdx396-F2){ref-type="fig"}D and E). Using hierarchical clustering, or dimensional reduction representations (tSNE), we grouped single cells based on their differential transcriptional profiles and identified two main subpopulations (Figure [3](#mdx396-F3){ref-type="fig"}A and B). We hypothesized that these two subpopulations may represent tumor subclones driven by either *KRAS* or *EGFR* activating mutations. To test this hypothesis, we first defined EGFR and KRAS distinctive transcriptional signatures by comparing primary lung adenocarcinoma specimens' mutant for *EGFR* or *KRAS* \[[@mdx396-B27]\] ([supplementary Tables S2 and S3](#sup5){ref-type="supplementary-material"}, available at *Annals of Oncology* online). Remarkably, *KRAS*-activated genes were upregulated in the less abundant subclone, while *EGFR*-related genes were activated in the remaining tumor cells (Figure [3](#mdx396-F3){ref-type="fig"}C and D). Indeed, we observed a significantly increased expression of the *KRAS*- or *EGFR*-signature genes in the minor and major subpopulation, respectively, supporting their distinct activities in the putative tumor subclones (Student's *t*-test, Figure [3](#mdx396-F3){ref-type="fig"}E and F). The putative *EGFR*-driven subclone showed a significant association to genes whose expression was altered following targeted EGFR inhibition *in vitro* ([supplementary Figure S1A](#sup1){ref-type="supplementary-material"}--D, available at *Annals of Oncology* online), further supporting a clonal separation of the oncogenes. Collectively, these results support the existence of two distinct tumor subclones driven by either *KRAS* or *EGFR* activating mutations. Surprisingly, we further noticed the increased expression of immune system related genes in the *KRAS*-driven subclone ([supplementary Figure S1E](#sup1){ref-type="supplementary-material"} and F, available at *Annals of Oncology* online). We analyzed the PD-L1 expression by IHC in patient brain metastasis, PDOX *KRAS* WT and PDOX *KRAS* Mut ([supplementary Figure S2](#sup2){ref-type="supplementary-material"}, available at *Annals of Oncology* online).

![Single-cell transcriptome profiles point to the presence of a *KRAS*-driven subclone. (A) Hierarchical clustering of 197 single cells (columns) derived from a capmatinib-resistant PDOX using the most variable gene sets \[[@mdx396-B32]\]. Cells are grouped into two putative subclones (column labels) and correlating gene sets are summarized in aspects. Displayed are the most variable aspects (rows) and their importance (row colors). (B) Gene expression variances between cells displayed as t-distributed stochastic neighbor embedding (t-SNE) representation using previous defined distances and cluster identities (as in A). (C) Gene expression signatures derived from *KRAS* (upper panel) or *EGFR* (lower panel) mutant primary lung adenocarcinomas \[[@mdx396-B27]\]. Gene expression levels of single cells are displayed as relative intensities \[[@mdx396-B22]\]. Displayed are the 25 most variant genes and signatures are summarized in the panel above (orange: overrepresented; green: underrepresented). (D) Mutational signature intensities of single cells. Cells are separated by their signature expression levels for *EGFR* and *KRAS* mutations. Cells were assigned to clusters as in (A). Direct comparison of *KRAS* (E) or *EGFR* (F) signature scores between the putative subclones (*KRAS*: red; *EGFR*: black). Significant differences between groups (Student's *t*-test) are indicated.](mdx396f3){#mdx396-F3}

The presence of minor *KRAS* mutant clones could be a clinically relevant mechanism of resistance to EGFR-TKIs and/or c-MET inhibitors and remain undetectable by standard techniques (NGS, qPCR, Sanger sequencing). Consequently, we used the most sensitive genetic assay, ddPCR \[[@mdx396-B23]\] for a retrospectively genetic profiling of *EGFR*-mutated lung cancer patient samples (Table [1](#mdx396-T1){ref-type="table"}). In the biopsies at the time of progression to EGFR-TKIs from 13 *EGFR*-mutated patients, we detected five *EGFR T790M* and three *KRAS G12C* mutant tumors. These patients were originally considered wild type for these alterations when evaluated with NGS (Table [1](#mdx396-T1){ref-type="table"}). Furthermore, none of the seven tumor samples evaluated from surgical early-stage NSCLC patients with the presence of mutation in *EGFR* and naïve to EGFR-TKIs presented *KRAS G12C* mutations. In one of the samples, we detected *EGFR T790M*. Table 1.Twenty EGFR-mutated lung cancer samples were assessed retrospectively by a ddPCR assayPatient sampleGenderSmoking habitPrevious lines of treatmentPrevious lines of TKITKIActivating *EGFR* mutationBaseline EGFR T790M (ddPCR)Baseline KRAS G12C (ddPCR)Progression to TKI EGFR T790M (ddPCR)Progression to TKI KRAS G12C (ddPCR)1FemaleFormer22Gefitinib Nazartinibex19delN/AN/A13.35%0.0027%2FemaleFormer21Erlotinibex19delN/AN/A1.60%0.14%3FemaleNever32Erlotinib Osimertinibp.L858RN/AN/AN/AWT4MaleFormer41Erlotinibex19delN/AN/AWTWT5FemaleNever42Erlotinib Nazartinibex19delN/AN/A76.30%WT6MaleFormer42Afatinib Nazartinibex19delN/AN/A12.20%WT7FemaleFormer32Afatinib Gefitinibex19delN/AN/AWTWT8FemaleNever11Erlotinibex19delN/AN/AWTWT9FemaleNever32Erlotinib Gefitinibp.L858RN/AN/AWT0.75%10FemaleNever72Erlotinib Gefitinibp.L858RN/AN/AWTWT11FemaleNever43Dacomitinib Nazartinib Osimertinibp.L858RN/AN/A95.75%WT12FemaleNever43Erlotinib Rociletinib Osimertinibex19delN/AN/AWTWT13FemaleFormer73Gefitinib Erlotinib Osimertinibex19delN/AN/AN/AWT14FemaleNeverNaive0Naiveex19delWTWTN/AN/A15MaleNeverNaive0Naivep.L858RWTWTN/AN/A16FemaleFormerNaive0Naiveex19delWTWTN/AN/A17FemaleNeverNaive0Naivep.L858RWTWTN/AN/A18MaleFormerNaive0NaiveDel p.V7690.33%WTN/AN/A19FemaleNeverNaive0Naivep.L858RWTWTN/AN/A20FemaleNeverNaive0Naiveex19delWTWTN/AN/A[^2]

Discussion
==========

In summary, we observed how a lung adenocarcinoma presenting an activating deletion of exon 19 in the *EGFR* gene acquired a second *T790M* mutation in the same gene upon treatment with erlotinib, while *MET* amplification was detected after subsequent osimertinib. In the same line, previous studies showed how MET copy number gain causes gefitinib resistance in CNS lesions utilizing mouse *in vivo* imaging models \[[@mdx396-B28]\]. At this point, we also detected *KRAS G12C* and *EGFR T790M* by ddPCR. Importantly, in a PDOX model, we demonstrated that this *MET* amplification is essential for lung cancer cell survival since capmatinib therapy proved very effective. Intriguingly, for the very first time, we show c-MET signaling inhibition with capmatinib to be more potent when combined with afatinib than as a single agent in our mouse model. This afatinib effect contrasted with its complete lack of activity as monotherapy. This benefit of combining afatinib could have been mediated by its previously described capacity to block *ERBB3* or *ERBB4* activations by heregulin ligand in EGFR mutant lung tumors \[[@mdx396-B29]\]. This inhibition of *ERBB3/4* or the inhibition of *EGFR* itself, are both possible mechanism that require further investigation. Our data suggest that this oncogenic ERBB activation would only be relevant for the survival of cancer cells addicted to hyperactive c-MET signaling. In this sense, c-MET and EGFR (*ERBB1*) form membrane heterodimers in normal and cancer cells leading to their trans-phosphorylation and activation of downstream MAPK pathway. Additionally, c-MET/KRAS/ERK signaling induces the transcription of EGF ligand and EGFR activation as a positive feedback loop. Further analyses will be required to confirm the relevance of such crosstalk between *EGFR* or *ERBB3/4* with c-MET as a molecular determinant of response to combined c-MET and EGFR blockade in advanced lung cancer.

Our results also evidence the extreme plasticity of lung adenocarcinoma genomes that evolve to adapt to as well as survive the pharmacological pressure of third-generation EGFR-TKIs. Could this be a consequence of selecting *de novo* mutations in lung cancer genomes or is it reflective of the early coexistence of multiple genetic clones with distinctive capacities to resist target-directed therapies? Our findings support the hypothesis of lung adenocarcinomas consisting of a complex map of genetic clones ready for selection under effective pharmacological pressure. We clearly observed the emergence of *KRAS G12C* mutant clones upon blocking two upstream activating components of the MAPK pathway such as EGFR or c-MET. Similarly, oncogenic *KRAS* mutations were described as resistance mechanisms to anti-EGFR antibodies in colorectal cancer \[[@mdx396-B30], [@mdx396-B31]\], a phenomenon that can also involve clonal enrichment upon treatment.

Indeed, we observed that drugs blocking EGFR or c-MET signaling preferentially promoted the emergence of genetic alterations in *EGFR*, *MET* and *KRAS* genes; all essential components of the oncogenic TKR/KRAS/MAPK pathway. This particular genetic evolution confirms the strict addiction of lung tumors to TKR/KRAS/MAPK pathway as a driving force of drug-resistance and disease progression. Consistent with our aforementioned observations, subsequent therapy should be assessed as a combination of the EGFR inhibitor with c-MET inhibitors.

In these highly heterogeneous lung tumor samples, we also noted a subpopulation of cells presenting a distinctive *KRAS* gene expression signature enriched in immune-related components. Indeed, initial clinical data indicate that *KRAS* mutant lung adenocarcinomas could be more sensitive to immune checkpoint inhibitors. Thus, we also suggest immunotherapy as a later line of treatment of those patients with *EGFR* mutant lung tumors that progress to consecutive lines of EGFR-TKIs and present emergence of *KRAS* mutant as well as potentially immunosensitive clones.

Finally, our data indicated that lung adenocarcinomas might evolve rapidly due to the surfacing of minor pre-existing genetic clones resistant to specific targeted therapies. Therefore, more complex therapies combining EGFR-TKIs with MET inhibitors and/or immunotherapy could be considered for lung cancer patients at earlier stages. This novel approach could prevent drug resistance and disease progression later on. For this reason, the clinical implementation of genetic technologies with higher sensitivity will be crucial in defining the genetic landscape of polyclonal tumors in patients' candidate to target-directed therapies.
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